Selected research
Industry Research
Canine Cancer Screening Industry Research Report 2026
Market perspective
The global Canine Cancer Screening market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Canine Cancer Screening market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Canine Cancer Screening market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Canine Cancer Screening market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Canine Cancer Screening include IDEXX, Mars Pedtcare, Zoetis, PetDx, Molecular Diagnostics (MDxHealth), Biomérieux SA, OncoK9, Antech Diagnostics and VolitionRx Limited, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Canine Cancer Screening market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Canine Cancer Screening.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Canine Cancer Screening Market by Company
IDEXX
Mars Pedtcare
Zoetis
PetDx
Molecular Diagnostics (MDxHealth)
Biomérieux SA
OncoK9
Antech Diagnostics
VolitionRx Limited
Oncotect
Heska Corporation
Canine Cancer Screening Segment by Type
Liquid Biopsy (Blood-Based Tests)
Tissue Biopsy
Genomic Testing
Biomarker Tests
Canine Cancer Screening Segment by Application
Veterinary Clinics
Veterinary Hospitals
Other
Canine Cancer Screening Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Canine Cancer Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Canine Cancer Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Canine Cancer Screening.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Canine Cancer Screening companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Liquid Biopsy (Blood-Based Tests)
- Tissue Biopsy
- Genomic Testing
- Biomarker Tests
Applications
- Veterinary Clinics
- Veterinary Hospitals
- Other
Companies covered
- IDEXX
- Mars Pedtcare
- Zoetis
- PetDx
- Molecular Diagnostics (MDxHealth)
- Biomérieux SA
- OncoK9
- Antech Diagnostics
- VolitionRx Limited
- Oncotect
- Heska Corporation
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Canine Cancer Screening by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Liquid Biopsy (Blood-Based Tests)
- 2.2.3 Tissue Biopsy
- 2.2.4 Genomic Testing
- 2.2.5 Biomarker Tests
- 2.3 Canine Cancer Screening by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Veterinary Clinics
- 2.3.3 Veterinary Hospitals
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Canine Cancer Screening Breakdown Data by Type
- 3.1 Global Canine Cancer Screening Historic Market Size by Type (2021-2026)
- 3.2 Global Canine Cancer Screening Forecasted Market Size by Type (2027-2032)
4 Canine Cancer Screening Breakdown Data by Application
- 4.1 Global Canine Cancer Screening Historic Market Size by Application (2021-2026)
- 4.2 Global Canine Cancer Screening Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Canine Cancer Screening Market Perspective (2021-2032)
- 5.2 Global Canine Cancer Screening Growth Trends by Region
- 5.2.1 Global Canine Cancer Screening Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Canine Cancer Screening Historic Market Size by Region (2021-2026)
- 5.2.3 Canine Cancer Screening Forecasted Market Size by Region (2027-2032)
- 5.3 Canine Cancer Screening Market Dynamics
- 5.3.1 Canine Cancer Screening Industry Trends
- 5.3.2 Canine Cancer Screening Market Drivers
- 5.3.3 Canine Cancer Screening Market Challenges
- 5.3.4 Canine Cancer Screening Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Canine Cancer Screening Players by Revenue
- 6.1.1 Global Top Canine Cancer Screening Players by Revenue (2021-2026)
- 6.1.2 Global Canine Cancer Screening Revenue Market Share by Players (2021-2026)
- 6.2 Global Canine Cancer Screening Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Canine Cancer Screening Head Office and Area Served
- 6.4 Global Canine Cancer Screening Players, Product Type & Application
- 6.5 Global Canine Cancer Screening Manufacturers Established Date
- 6.6 Global Canine Cancer Screening Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Canine Cancer Screening Market Size (2021-2032)
- 7.2 North America Canine Cancer Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Canine Cancer Screening Market Size by Country (2021-2026)
- 7.4 North America Canine Cancer Screening Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Canine Cancer Screening Market Size (2021-2032)
- 8.2 Europe Canine Cancer Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Canine Cancer Screening Market Size by Country (2021-2026)
- 8.4 Europe Canine Cancer Screening Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Canine Cancer Screening Market Size (2021-2032)
- 9.2 Asia-Pacific Canine Cancer Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Canine Cancer Screening Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Canine Cancer Screening Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Canine Cancer Screening Market Size (2021-2032)
- 10.2 South America Canine Cancer Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Canine Cancer Screening Market Size by Country (2021-2026)
- 10.4 South America Canine Cancer Screening Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Canine Cancer Screening Market Size (2021-2032)
- 11.2 Middle East & Africa Canine Cancer Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Canine Cancer Screening Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Canine Cancer Screening Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 IDEXX
- 12.1.1 IDEXX Company Information
- 12.1.2 IDEXX Business Overview
- 12.1.3 IDEXX Revenue in Canine Cancer Screening Business (2021-2026)
- 12.1.4 IDEXX Canine Cancer Screening Product Portfolio
- 12.1.5 IDEXX Recent Developments
- 12.2 Mars Pedtcare
- 12.2.1 Mars Pedtcare Company Information
- 12.2.2 Mars Pedtcare Business Overview
- 12.2.3 Mars Pedtcare Revenue in Canine Cancer Screening Business (2021-2026)
- 12.2.4 Mars Pedtcare Canine Cancer Screening Product Portfolio
- 12.2.5 Mars Pedtcare Recent Developments
- 12.3 Zoetis
- 12.3.1 Zoetis Company Information
- 12.3.2 Zoetis Business Overview
- 12.3.3 Zoetis Revenue in Canine Cancer Screening Business (2021-2026)
- 12.3.4 Zoetis Canine Cancer Screening Product Portfolio
- 12.3.5 Zoetis Recent Developments
- 12.4 PetDx
- 12.4.1 PetDx Company Information
- 12.4.2 PetDx Business Overview
- 12.4.3 PetDx Revenue in Canine Cancer Screening Business (2021-2026)
- 12.4.4 PetDx Canine Cancer Screening Product Portfolio
- 12.4.5 PetDx Recent Developments
- 12.5 Molecular Diagnostics (MDxHealth)
- 12.5.1 Molecular Diagnostics (MDxHealth) Company Information
- 12.5.2 Molecular Diagnostics (MDxHealth) Business Overview
- 12.5.3 Molecular Diagnostics (MDxHealth) Revenue in Canine Cancer Screening Business (2021-2026)
- 12.5.4 Molecular Diagnostics (MDxHealth) Canine Cancer Screening Product Portfolio
- 12.5.5 Molecular Diagnostics (MDxHealth) Recent Developments
- 12.6 Biomérieux SA
- 12.6.1 Biomérieux SA Company Information
- 12.6.2 Biomérieux SA Business Overview
- 12.6.3 Biomérieux SA Revenue in Canine Cancer Screening Business (2021-2026)
- 12.6.4 Biomérieux SA Canine Cancer Screening Product Portfolio
- 12.6.5 Biomérieux SA Recent Developments
- 12.7 OncoK9
- 12.7.1 OncoK9 Company Information
- 12.7.2 OncoK9 Business Overview
- 12.7.3 OncoK9 Revenue in Canine Cancer Screening Business (2021-2026)
- 12.7.4 OncoK9 Canine Cancer Screening Product Portfolio
- 12.7.5 OncoK9 Recent Developments
- 12.8 Antech Diagnostics
- 12.8.1 Antech Diagnostics Company Information
- 12.8.2 Antech Diagnostics Business Overview
- 12.8.3 Antech Diagnostics Revenue in Canine Cancer Screening Business (2021-2026)
- 12.8.4 Antech Diagnostics Canine Cancer Screening Product Portfolio
- 12.8.5 Antech Diagnostics Recent Developments
- 12.9 VolitionRx Limited
- 12.9.1 VolitionRx Limited Company Information
- 12.9.2 VolitionRx Limited Business Overview
- 12.9.3 VolitionRx Limited Revenue in Canine Cancer Screening Business (2021-2026)
- 12.9.4 VolitionRx Limited Canine Cancer Screening Product Portfolio
- 12.9.5 VolitionRx Limited Recent Developments
- 12.10 Oncotect
- 12.10.1 Oncotect Company Information
- 12.10.2 Oncotect Business Overview
- 12.10.3 Oncotect Revenue in Canine Cancer Screening Business (2021-2026)
- 12.10.4 Oncotect Canine Cancer Screening Product Portfolio
- 12.10.5 Oncotect Recent Developments
- 12.11 Heska Corporation
- 12.11.1 Heska Corporation Company Information
- 12.11.2 Heska Corporation Business Overview
- 12.11.3 Heska Corporation Revenue in Canine Cancer Screening Business (2021-2026)
- 12.11.4 Heska Corporation Canine Cancer Screening Product Portfolio
- 12.11.5 Heska Corporation Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst